Clinical Trial Update: Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating lenalidomide to reverse drug resistance after first-line treatment in advanced hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Shenyang Tenth People's Hospital | Conditions: Advanced HCC | Phase 2 | Status: UNKNOWN